Skip to main content

Table 4 Information on diabetes medications for the 41 study patients in the 3 groups

From: Glycated hemoglobin and glycated albumin in patients with diabetes undergoing hemodiafiltration

 

Group A

Non-protein-leaking OHDF

Group B

Protein-leaking OHDF

Group C

Highly efficient protein-leaking OHDF

Number of patients

20

14

7

Insulin users (number)

3

5

2

 Dipeptidyl peptidase-4 inhibitor (number)

1

3

2

 α-Glucosidase inhibitor (number)

0

0

1

 Glucagon-like peptide-1 receptor agonist (number)

1

1

0

 Glinide (number)

0

1

2

 Sulfonylurea (number)

0

0

0

Non-insulin users (number)

14

7

2

 Dipeptidyl peptidase-4 inhibitor (number)

13

6

2

 α-Glucosidase inhibitor (number)

5

1

1

 Glucagon like peptide-1 receptor agonist (number)

1

1

0

 Glinide (number)

0

3

0

 Sulfonylurea (number)

1

0

0

Unused diabetes medications (number)

3

2

3

  1. Including multiple users of diabetes medications